22036-webinar-target-rwe-850x200 (1).jpg

Watch On Demand!

How can we generate real world data (RWD) and real world evidence (RWE) by bringing together academia, industry, regulatory authorities, and patient advocacy representatives?

  • Collaboration leads to joint real-world studies, publications, and meeting presentations that better inform the medical community
  • Collaboration with academia, community investigators, pharma, and patient advocacy communities requires special considerations and approaches
  • Collaboration with regulatory stakeholders leads to alignment with dynamic and continuously evolving RWE framework and guidelines
  • In doing so, analytics and outputs can remain at the forefront of new RWE expectations and requirements
  • Process of creating RWE disease communities, partnerships with stakeholders, and tying advanced analytics from a variety of datasets to report on the RWD

Featured Topics include:

  • Why collaborate in the first place?
  • Considering needs and goals of industry partners and stakeholder identification
  • Building academic/community collaboration and partnerships
  • Including regulatory stakeholders in the collaboration process
  • Listening to the patient advocacy community
  • Bringing all stakeholders together with the end goal of generating meaningful real-world evidence that can improve patient care
Please note that this is an exhibitor sponsored event and is not eligible for CE credit.


   Michael W. Fried, MD, FAASLD, Co-Founder and Chief Medical Officer, Target RWE